Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥â¯60 years, by time since infection, Italy, 12 September to 11 December 2022.
Euro Surveill
; 28(8)2023 02.
Article
em En
| MEDLINE
| ID: mdl-36820640
ABSTRACT
Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI -44 to 44). A second booster vaccination 6â¯months after the latest infection may be warranted.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
COVID-19
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article